Superior Vena Cava Syndrome

Abdul Hussain Azizi; Irfan Shafi; Neal Shah; Kenneth Rosenfield; Robert Schainfeld; Akhilesh Sista; Riyaz Bashir

doi:10.1016/j.jcin.2020.08.038

Superior Vena Cava Syndrome

JACC Cardiovasc Interv. 2020 Dec 28;13(24):2896-2910. doi: 10.1016/j.jcin.2020.08.038.

Authors

Abdul Hussain Azizi¹, Irfan Shafi², Neal Shah¹, Kenneth Rosenfield³, Robert Schainfeld³, Akhilesh Sista⁴, Riyaz Bashir⁵

Affiliations

¹ Department of Internal Medicine, Temple University Hospital, Philadelphia, Pennsylvania, USA.
² Department of Internal Medicine, Detroit Medical Center, Wayne State University, Detroit, Michigan, USA.
³ Department of Cardiovascular Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
⁴ Department of Interventional Radiology, NYU Langone Health, New York, New York, USA.
⁵ Department of Cardiovascular Diseases, Temple University Hospital, Philadelphia, Pennsylvania, USA. Electronic address: riyaz.bashir@tuhs.temple.edu.

PMID: 33357528
DOI: 10.1016/j.jcin.2020.08.038

Abstract

Superior vena cava (SVC) syndrome comprises a constellation of clinical signs and symptoms caused by obstruction of blood flow through the SVC. The management of patients with life-threatening SVC syndrome is evolving from radiation therapy to endovascular therapy as the first-line treatment. There is a paucity of data and societal guidelines with regard to the management of SVC syndrome. This paper aims to update the practicing interventionalists with the contemporary and the evolving therapeutic approach to SVC syndrome. In addition, the review will focus on endovascular techniques, including catheter-directed thrombolysis, angioplasty, and stenting, and their associated complications.

Keywords: catheter-directed thrombolysis; endovascular therapy; superior vena cava obstruction.

Publication types

Review

MeSH terms

Endovascular Procedures
Humans
Stents
Superior Vena Cava Syndrome*
Treatment Outcome
Vena Cava, Superior